Product Description
For Retinal Vasculopathy Cerebral Leukoencephalopathy; crizanlizumab is a humanized monoclonal anti-P-selectin antibody that prevents leukocyte adhesion to the vascular endothelium, thereby limiting risk of microvascular occlusion (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04611880)
Mechanisms of Action: P-selectin Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Colombia | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Saudi Arabia | Slovakia | Spain | Sweden | United Arab Emirates | United Kingdom | United States
Approved Indications: Anemia, Sickle Cell
Known Adverse Events: Back Pain | Pain Unspecified | Arthralgia
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Brazil, Canada, Colombia, Finland, France, Germany, Ghana, Greece, India, Ireland, Italy, Jordan, Lebanon, Netherlands, Oman, Panama, South Africa, Spain, Switzerland, Turkey, United Kingdom, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Anemia, Sickle Cell
Phase 2: Kidney Failure, Chronic|Priapism
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SPARKLE | P3 |
Not yet recruiting |
Anemia, Sickle Cell |
2029-03-23 |
56% |
| SEG101 | P2 |
Not yet recruiting |
Anemia, Sickle Cell |
2028-07-01 |
|
| STAND | P3 |
Unknown status |
Anemia, Sickle Cell |
2027-11-08 |
|
| CSEG101A2301 | P3 |
Unknown Status |
Anemia, Sickle Cell |
2026-12-14 |